Weight Loss Medication UK: Options in 2026

If you've been reading about weight loss medication lately and feeling a bit overwhelmed by the sheer number of options, names, and headlines — you're not alone. The landscape has shifted dramatically in the last couple of years, and what was once a conversation limited to a few options and willpower has become something far more nuanced.

The truth is, weight loss medication works. Not for everyone, and not in isolation — but for the right person, in the right circumstances, it can be life-changing. What matters is understanding which treatments exist, how they actually work in your body, and whether any of them might be appropriate for you.

What weight loss medications are available in the UK?

The options available right now fall into a few categories depending on their mechanism of action. Understanding the differences is important — not just for choosing the right one, but for setting realistic expectations about what any given treatment can and can't do for you.

GLP-1 receptor agonists (injectable)

This is where most of the excitement — and most of the media coverage — has been concentrated. GLP-1 receptor agonists mimic a hormone your gut naturally produces after eating. They work on several levels simultaneously: slowing gastric emptying so food stays in your stomach longer, signalling to your brain that you're satisfied, and reducing those persistent cravings that make sustained weight loss so difficult.

Semaglutide (Wegovy) was the first to receive MHRA approval specifically for weight management in the UK. It's administered as a once-weekly subcutaneous injection — a small needle into the fatty tissue of your abdomen, thigh, or upper arm. The dosing starts low (0.25mg weekly) and increases gradually over 16 weeks to the maintenance dose of 2.4mg.

In the STEP clinical trials, participants on semaglutide lost an average of 14.9% of their body weight over 68 weeks. For someone weighing 100kg, we're talking about roughly 15kg in weight loss. But the numbers only tell part of the story. What patients consistently report is a fundamental shift in their relationship with food. The constant mental negotiation — should I eat this, shouldn't I — starts to quieten.

Tirzepatide (Mounjaro) takes things a step further. It targets two hormones rather than one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism produced even more pronounced results in the SURMOUNT trials, with average weight loss of around 22.5% at the highest dose over 72 weeks.

Mounjaro is available in the UK through online pharmacies and private prescriptions. The dosing follows a similar titration pattern — starting at 2.5mg weekly and increasing to a maximum of 15mg, depending on how you respond and what your prescriber recommends.

Orlistat (Xenical / Alli)

Orlistat works through an entirely different mechanism. Rather than affecting appetite or hormones, it blocks the absorption of roughly a third of the dietary fat you consume. The enzyme lipase, which normally breaks down fat in your gut, gets inhibited — so that fat passes through your system undigested.

The 120mg prescription-strength version (Xenical) is available from your GP or an online prescriber. A lower 60mg dose (Alli) can be purchased over the counter at pharmacies without a prescription — making it the only weight loss medication you can buy directly in the UK.

Orlistat tends to produce more modest results than the injectable treatments — typically 5–10% of body weight over 12 months. It also comes with some well-documented gastrointestinal side effects (oily stools, urgency, flatulence) that are directly related to the unabsorbed fat. These side effects are unpleasant but serve an accidental purpose: they make high-fat meals genuinely unappealing, which some people find helps them stick to a lower-fat diet.

Emerging treatments

The weight loss medication space is evolving rapidly. A few treatments worth knowing about:

Oral semaglutide — Novo Nordisk is developing a tablet form of semaglutide for weight management (separate from the Rybelsus diabetes tablet), which could remove the injection barrier entirely. Clinical data has been promising, with weight loss approaching that of the injectable version.

Survodutide and retatrutide — next-generation treatments targeting three receptors rather than two. These are still in clinical trials but early data suggests even greater efficacy. Retatrutide, for instance, showed up to 24% weight loss in Phase 2 trials.

CagriSema — a combination of semaglutide and cagrilintide that's shown particularly impressive results in trials, with some participants losing over 25% of their body weight.

None of these are available yet in the UK, but they're worth keeping an eye on if you're considering your options.

How do weight loss medications actually work?

It's tempting to think of weight loss medication as simply "appetite suppressants," but that undersells what's happening at a physiological level — particularly with the newer GLP-1 treatments.

Your body has a complex system for regulating hunger and energy balance. It involves hormones like leptin, ghrelin, GLP-1, GIP, and insulin, along with neural pathways between your gut and brain. When you lose weight through diet alone, your body fights back: ghrelin (the hunger hormone) increases, leptin (the satiety hormone) drops, and your metabolic rate decreases. This isn't a character flaw — it's biology. Your body believes it's protecting you from starvation.

GLP-1 medications work with this system rather than against it. By providing a sustained GLP-1 signal, they essentially recalibrate the set point. Patients describe it as the removal of "food noise" — that relentless background chatter about when and what to eat next. It's not that food becomes unpleasant. It's that the compulsive quality of thinking about it fades.

Orlistat bypasses this hormonal system entirely. It works mechanically in the gut, and it doesn't reduce appetite. For some people, this is actually preferable — particularly if they don't struggle with appetite per se but find it difficult to limit fat intake.

Who is eligible for weight loss medication in the UK?

Eligibility criteria vary depending on the specific treatment, but the general framework is consistent:

For prescription-only treatments (Wegovy, Mounjaro, Orlistat 120mg):

You'll typically need a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition — type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea, among others.

For over-the-counter Orlistat (Alli, 60mg):

A BMI of 28 or above, purchased through a pharmacist who will check your suitability.

For NHS prescriptions specifically:

Access via the NHS is more restricted. While Wegovy received NHS approval in 2023, actual availability has been inconsistent due to supply issues and local commissioning decisions. The NHS Tier 3 weight management pathway does offer these treatments, but waiting lists can be lengthy. Many people in the UK access GLP-1 medications through private online pharmacies instead.

Beyond BMI numbers, a responsible prescriber will also consider your medical history, current medications, and whether you've attempted lifestyle modifications previously. Weight loss medication interacts with other drugs and conditions, and not every treatment suits every person.

Certain conditions rule out GLP-1 treatments entirely: a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a history of pancreatitis. If you're pregnant, planning pregnancy, or breastfeeding, these medications aren't appropriate either.

Comparing the main weight loss medications

Worth noting: these average figures come from clinical trial populations, which tend to be more adherent and closely monitored than real-world use. Your individual results will depend on your starting point, how consistently you take the medication, and the lifestyle changes you make alongside it.

What about side effects?

GLP-1 medications (Wegovy and Mounjaro)

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These tend to be most noticeable during the dose titration phase — the first 8–16 weeks when your body is adjusting to the medication.

For most people, nausea is the dominant early experience. It's usually mild to moderate and improves substantially as you settle onto your maintenance dose. Eating smaller meals, avoiding very fatty or rich foods, and not lying down immediately after eating can all help.

Less common but more serious potential side effects include pancreatitis (rare but requires immediate medical attention if you develop severe, persistent abdominal pain), gallbladder problems (gallstones occur more frequently with rapid weight loss generally, not just with medication), and — very rarely — thyroid tumours. The thyroid risk has been observed in animal studies but hasn't been confirmed in humans to date.

Some people also report fatigue, headaches, and dizziness, particularly in the early weeks. These almost always resolve.

Orlistat

The side effects here are almost entirely gastrointestinal and directly related to dietary fat intake. If you eat a high-fat meal while taking Orlistat, you will likely experience oily or fatty stools, increased bowel movements, flatulence with oily discharge, and stomach pain or discomfort. Keeping your dietary fat below roughly 15g per meal minimises these effects significantly.

Weight loss medication on the NHS vs. private prescriptions

This is one of the most common questions we hear, and the honest answer is that NHS access to newer weight loss medications remains patchy.

The NHS pathway typically involves being referred to a Tier 3 specialist weight management service by your GP. These services offer multidisciplinary support — dietitians, psychologists, exercise specialists — alongside potential medication. Wegovy and, more recently, Mounjaro have been approved by NICE for NHS use, but real-world availability depends heavily on where you live and local commissioning decisions. Waiting times for Tier 3 services can stretch to 12 months or more in some areas.

Your GP can prescribe Orlistat directly without a specialist referral, making it the most accessible NHS option.

Private online pharmacies have filled the gap for many people who want access to GLP-1 treatments without lengthy NHS waits. These services typically involve an online medical questionnaire, a review by a registered prescriber (often a GP or pharmacist independent prescriber), and delivery of the medication to your door.

Costs vary. Wegovy typically runs £100–£229 per month privately, while Mounjaro ranges from £129 at the lowest dose to around £329 at higher doses. Some providers offer subscription models or payment plans.

A word of caution here: not all online providers are equal. Look for services registered with the General Pharmaceutical Council (GPhC) or the Care Quality Commission (CQC). Any legitimate provider will require a proper medical consultation before prescribing — if someone offers to sell you GLP-1 medication without asking about your health, that's a red flag.

Can you get weight loss pills over the counter in the UK?

The short answer: yes, but your options are limited.

Alli (Orlistat 60mg) is the only clinically proven weight loss medication available without a prescription in the UK. You'll need to speak with a pharmacist who will check your BMI and ask about your health before selling it to you.

Beyond Alli, you'll find a vast marketplace of supplements, herbal products, and "fat burners" marketed for weight loss. Products containing ingredients like glucomannan, green tea extract, or conjugated linoleic acid (CLA) are widely available. The evidence for most of these ranges from weak to nonexistent. Some may produce very small effects — glucomannan, for instance, has shown modest weight loss in some studies — but nothing comparable to prescription medications.

Be particularly cautious about products sold online from unregulated sources. There have been cases of supplements containing undeclared pharmaceutical ingredients, including substances that have been withdrawn from the market for safety reasons.

How to decide which weight loss medication is right for you

There's no single "best" weight loss medication — the right choice depends on your circumstances, preferences, and what you're prepared to commit to.

Consider a GLP-1 injection if: your BMI is 30+ (or 27+ with comorbidities), you've struggled with appetite control and food cravings, you're comfortable with self-injecting once weekly, and you can budget for the ongoing cost if going private.

Consider Orlistat if: you prefer a tablet to an injection, your weight loss goal is more modest (5–10%), cost is a primary concern, or you want something available on the NHS without specialist referral.

Consider over-the-counter Alli if: you want to start something without a prescription, your BMI is between 28–30, and you're making concurrent dietary changes.

Whatever you choose, medication works best as part of a broader approach. That means paying attention to nutrition — not necessarily following a rigid diet, but making sustainable shifts towards more protein, more vegetables, and fewer ultra-processed foods. It means finding movement you can maintain long-term. And it means addressing the psychological aspects of eating, because food serves emotional functions that no medication can replace.

What happens when you stop taking weight loss medication?

This is a question that doesn't get enough discussion.

The clinical evidence is clear: most people regain a significant portion of lost weight after stopping GLP-1 medication. The STEP 1 extension trial showed that participants regained approximately two-thirds of their weight loss within a year of stopping semaglutide.

This isn't a failure of the medication or of the person taking it. It reflects the underlying biology — the same hormonal and metabolic pressures that made weight loss difficult in the first place return when the medication is removed.

For many people, this means weight loss medication is a long-term treatment rather than a short course. That has implications for cost, convenience, and how you think about the commitment involved.

Some emerging research suggests that building strong lifestyle habits while on medication — and tapering slowly rather than stopping abruptly — may help retain more of the weight loss. But this is an area where the science is still catching up with the clinical reality.

The bottom line

Weight loss medication in the UK has advanced in the last few years. GLP-1 treatments like Wegovy and Mounjaro offer a level of efficacy that simply wasn't available before — and for many people, they represent the first time a medical treatment has matched the scale of the challenge they face.

But medication isn't a standalone solution, and it's not appropriate for everyone. The best outcomes come from combining the right treatment with sustainable lifestyle changes and proper medical oversight.

If you're considering weight loss medication, the most important first step is having an honest medical consultation — whether that's with your GP, a specialist weight management service, or a regulated online prescriber. Understanding your options fully, including the costs, side effects, and long-term commitment involved, puts you in the best position to make a decision that works for your life.

Frequently asked questions

What is the most effective weight loss medication in the UK?

Based on clinical trial data, tirzepatide (Mounjaro) currently shows the highest average weight loss — around 20–22% of body weight over 72 weeks at the maximum dose. Semaglutide (Wegovy) follows closely at approximately 15%. However, "most effective" depends on the individual. Some people respond better to one treatment than another, and factors like tolerability, cost, and medical history all influence what's genuinely best for you.

Can my GP prescribe weight loss medication?

Yes. Your GP can prescribe Orlistat directly, and in some cases can prescribe GLP-1 medications like Wegovy or Mounjaro — though this varies by local commissioning arrangements. More commonly, GLP-1 treatments are accessed through specialist weight management services (via GP referral) or through private online pharmacies.

How much does weight loss medication cost privately in the UK?

Orlistat is the most affordable at roughly £25–£50 per month. GLP-1 injections are significantly more expensive: Wegovy typically costs £100–£229/month and Mounjaro ranges from £129–£329/month depending on the dose. Some providers offer subscription discounts or split payment options. These costs are ongoing for as long as you take the medication.

Are weight loss injections safe?

GLP-1 weight loss injections (Wegovy, Mounjaro) have been through extensive clinical trials involving tens of thousands of participants and have received regulatory approval from both the MHRA (UK) and FDA (US). Like all medications, they carry side effects — most commonly nausea and other gastrointestinal symptoms, especially during the initial dose titration. Serious adverse events are rare. A thorough medical assessment before starting treatment is essential to identify any contraindications.

Do I need to diet and exercise while taking weight loss medication?

Weight loss medication works best alongside lifestyle changes, and all the clinical trials demonstrating their effectiveness included dietary guidance and physical activity recommendations. You don't need to follow a specific diet plan, but paying attention to protein intake, reducing ultra-processed foods, and finding sustainable movement will improve your results and your overall health — with or without medication.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.